Clinical trials: Meals
Healthy
Fed Bioequivalence Study of Fenofibric Acid Versus TriCor® (Fenofibrate)
This study will evaluate the bioequivalence of 105 mg fenofibric acid tablets relative to 145 mg fenofibrate tablets in healthy volunteers when administered following a breakfast of standard composition.
- Trial name
- NCT00960687
- Testing
- Fenofibric Acid (Fibricor™) 105 mg Tablet, Fenofibrate (Tricor®) 145 mg Tablet
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Diabetes Mellitus, Type 1
SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1
Primary objective: To compare metabolic control as measured by Blood Glucose (BG) upon arising from bed (7:00 am - 12:00 pm) in type 1 Diabetes mellitus patients who skip the morning meal during treatment with MDI basal/bolus…
- Trial name
- NCT00313937
- Testing
- Insulin glargine
- Where
- Germany
- Volunteers
- 91 people
- Sponsor
- Sanofi
Healhty
A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants
WD-1603 contains two different drugs called levodopa and carbidopa in one tablet. The goal of this clinical trial is to see if taking the study drug WD-1603 at different time intervals affects how the drug acts in healthy…
- Trial name
- NCT07442591
- Testing
- Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.
This is an open-label single-arm observational trial to study the effectiveness of a commercially available meal-replacement shake and its effect on the quality of life in individuals with type 2 diabetes.
- Trial name
- NCT05129735
- Testing
- Meal replacement shake
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Teatis, Inc
Healthy
A Study on the Bioequivalence of Perindopril Tert-butylamine Tablets Taken on After Meals in Healthy Subjects
In order to evaluate the bioequivalence of the test preparation and reference preparation of perindopril tert-butylamine tablets after meal and their safety in Chinese adult healthy subjects.
- Trial name
- NCT04556110
- Testing
- Perindopril tert-Butylamine tablets （ Produced by Haisco）, Perindopril tert-Butylamine tablets（ACERTIL®）
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Osteoarthritis, Osteoarthritis, Knee
A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women
The purpose of this study is to evaluate the efficacy of hydrolyzed collagen in osteoarthritis.
- Conditions
- Osteoarthritis, Osteoarthritis, Knee, Osteoarthritis, Hip
- Trial name
- NCT05070871
- Testing
- Hydrolyzed Collagen, CalGo
- Where
- 3 sites in Norway
- Volunteers
- 98 people
- Sponsor
- Hofseth Biocare ASA
Healthy
Study to Investigate the Relative Bioavailability of Ibuprofen in Healthy Volunteers
Study to demonstrate average bioequivalence between a 400 mg ibuprofen extrudate tablet (Test) and a 400 mg ibuprofen lysinate tablet (Dolormin extra ®; reference 1) under fasted conditions.
- Trial name
- NCT02183012
- Testing
- Ibuprofen extrudate, Ibuprofen lysinate, Ibuprofen
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Subjects
A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021
Part A: a single-center, randomized, open-label, three-cycle study to evaluate the pharmacokinetic (PK) profile of different doses of ABSK021 Capsules and the effect of a high-fat meal on the pharmacokinetic profile of ABSK021…
- Trial name
- NCT06322706
- Testing
- ABSK021, Omeprazole
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Abbisko Therapeutics Co, Ltd
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effect of canagliflozin on post-meal glucose blood levels in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01381887
- Testing
- Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy Volunteers
Phase I Clinical Study of MWN109 Tablets in Healthy Chinese Participants
This is a randomized, double-blind, placebo-controlled, Phase 1 clinical study conducted in China to evaluate the safety, tolerability, pharmacokinetic (PK), and the effect of meal timing following single and multiple oral doses…
- Trial name
- NCT07787611
- Testing
- MWN109 tablet
- Where
- China
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Benign Prostatic Hyperplasia
Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers After Meal
This study is an open-label, randomized, fed, single dose, crossover study to evaluate the bioequivalence of Chong Kun Dang Pharmaceutical "Chong Kun Dang Tamsulosin HCl Tablet" and Astellas Phama Korea Inc.
- Trial name
- NCT03887871
- Testing
- Harnal-D Tab., Chong Kun Dang Tamsulosin HCl Tab.
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Pharmacokinetics
Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers
Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics of a single oral dose of finerenone (1.25 mg…
- Trial name
- NCT02956109
- Testing
- Finerenone (BAY94-8862): 1 0mg tablet, Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets, Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Prediabetes, Hypertension
Fasting Predictors of OGTT and MMTT Response
1. To develop a database containing matched information from dynamic tests of postprandial glycemic control (OGTT or MMTT), results of a broad panel of fasting biomarkers, and clinical information related to diabetes risk obtain…
- Conditions
- Prediabetes, Hypertension, Obesity, Cardiovascular Disease
- Trial name
- NCT01998867
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Health Diagnostic Laboratory, Inc.
Hypogonadism
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
A Phase 2, open-label, randomized, cross-over, pharmacokinetic study designed to determine the effect of meals of various amounts of fat given immediately prior to dosing on the pharmacokinetics of oral testosterone undecanoate.
- Trial name
- NCT02921386
- Testing
- Oral Testosterone Undecanoate
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Clarus Therapeutics, Inc.
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of biphasic insulin aspart 30 in subjects with type 1 or type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01467323
- Testing
- biphasic insulin aspart, biphasic human insulin
- Where
- 37 sites in Austria, Germany and 3 more
- Volunteers
- 303 people
- Sponsor
- Novo Nordisk A/S
Healthy
A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation
The purpose of this study is to (1) evaluate the effect of caloric intake on the pharmacokinetics of a single dose of a 330 mg pregabalin controlled release tablet relative to a 300 mg pregabalin immediate release capsule…
- Trial name
- NCT01080612
- Testing
- 330 mg pregabalin controlled release, 300 mg pregabalin immediate release
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy Subjects
Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects
A Study to determine if a high-fat meal has an effect on the pharmacokinetics of bosutinib.
- Trial name
- NCT00721474
- Testing
- Bosutinib
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postprandial Hyperglycemia
Determination of the GI and II Values of Soft Drink and Soft Drink With Sugardown™
This study was a partly controlled laboratory-based study comparing the glycemic and insulinemic indices of 3 test meals containing soft drink alone or with SUGARDOWN™ (Galactomannan) in overweight adults.
- Trial name
- NCT03374501
- Testing
- Sugardown™, Soft drink
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Boston Therapeutics
Heart Failure
Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal
The goal of this randomized double-blind crossover study is to assess whether a morning dose of the extended release torsemide has a better efficacy than the ordinary immediate release torsemide to induce renal sodium excretion…
- Trial name
- NCT06176794
- Testing
- Immediate release torsemide 20mg tablet, Extended release torsemide 24mg tablet
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Healthy
Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers
The objective of the present study is to investigate the relative bioavailability of BIIL 284 BS boli in comparison to the tablet C at a dose of 75 mg in fasted condition and after a standard breakfast in healthy male volunteers
- Trial name
- NCT02265640
- Testing
- BIIL 284 BS boli, BIIL 284 BS tablet C, standard breakfast
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim